Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from Renalytix AI (RNLX) is now available.
Renalytix plc announced that its KidneyIntelX™ product has been included in the final 2024 KDIGO guidelines for Chronic Kidney Disease, marking a significant endorsement from the medical community. This inclusion is not just a milestone for the company but also an important development for investors to watch, as it showcases the product’s growing recognition and potential impact on Renalytix’s market position.
See more data about RNLX stock on TipRanks’ Stock Analysis page.